NLS Pharmaceutics AG (NLSP)
NASDAQ: NLSP
· Real-Time Price · USD
2.28
-0.11 (-4.60%)
At close: Jun 13, 2025, 3:59 PM
2.23
-2.19%
After-hours: Jun 13, 2025, 07:55 PM EDT
Company Description
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders.
The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).
Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD.
The company was incorporated in 2015 and is based in Zurich, Switzerland.
NLS Pharmaceutics AG
| Country | CH |
| IPO Date | Jan 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Alexander Zwyer M.B.A. |
Contact Details
Address: The Circle 6 Zurich, CH | |
| Website | https://nlspharma.com |
Stock Details
| Ticker Symbol | NLSP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001783036 |
| CUSIP Number | H57830103 |
| ISIN Number | CH0523961370 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alexander Zwyer M.B.A. | Co-Founder, Chief Executive Officer & Director |
| Dr. Eric Konofal M.D., Ph.D. | Co-Founder & Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 10, 2025 | 6-K | Filing |
| Jun 09, 2025 | F-4/A | [Amend] Filing |
| Jun 06, 2025 | 425 | Filing |
| Jun 06, 2025 | 6-K | Filing |
| May 16, 2025 | 20-F | Filing |
| May 05, 2025 | 6-K | Filing |
| May 01, 2025 | NT 20-F | Filing |
| Apr 24, 2025 | 6-K | Filing |
| Apr 15, 2025 | 425 | Filing |
| Apr 15, 2025 | 6-K | Filing |